Effect of statin treatments on highly pathogenic avian influenza H5N1, seasonal and H1N1pdm09 virus infections in BALB/c mice

Future Virology

Volumn 7, Issue 8, 2012, Pages 801-818

  Kumaki, Yohichi ^a   Morrey, John D ^a   Barnard, Dale L ^a  

^a UTAH STATE UNIVERSITY   (United States)

Author keywords

anti inflammatory; atorvastatin; BALB c mouse; influenza virus; lovastatin; mevastatin; pitavastatin; rosuvastatin; simvastatin; statin

Indexed keywords

ATORVASTATIN; CERIVASTATIN; COMPACTIN; FAVIPIRAVIR; FLUINDOSTATIN; MEVINOLIN; PITAVASTATIN; PRAVASTATIN; RIBAVIRIN; ROSUVASTATIN; SIMVASTATIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL OXYGEN SATURATION; ARTICLE; AVIAN INFLUENZA VIRUS; BAGG ALBINO MOUSE; CONTROLLED STUDY; DEATH; FEMALE; INFLUENZA A (H1N1); INFLUENZA A (H3N2); INFLUENZA A (H5N1); INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS A H5N1; LUNG FUNCTION; LUNG WEIGHT; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEASONAL INFLUENZA; SURVIVOR; WEIGHT REDUCTION;

AVES; MUS; ORTHOMYXOVIRIDAE;

EID: 84865480996     PISSN: 17460794     EISSN: 17460808     Source Type: Journal    
DOI: 10.2217/fvl.12.71     Document Type: Article

References (74)

1. Cheng KF, Leung PC. What happened in China during the 1918 influenza pandemic? Int. J. Infect. Dis. 11(4), 360-364 (2007). (Pubitemid 46990979)
2. Kaye D, Pringle CR. Avian influenza viruses and their implication for human health. Clin. Infect. Dis. 40(1), 108-112 (2005). (Pubitemid 40053466)
3. Miller-Meeks M. Flu season and the threat of a pandemic. Iowa Med 96(6), 8 (2006).
4. Parry J. Conference urges greater effort to reduce human threat from avian influenza. BMJ 334(7594), 607 (2007).
5. Beigel JH, Farrar J, Han AM et al. Avian influenza A (H5N1) infection in humans. N. Engl. J. Med. 353(13), 1374-1385 (2005). (Pubitemid 41362705)
6. Whitley RJ, Monto AS. Seasonal and pandemic influenza preparedness: A global threat. J. Infect. Dis. 194(Suppl. 2), S65-S69 (2006). (Pubitemid 44630947)
7. Kumar S, Henrickson KJ. Update on influenza diagnostics: Lessons from the novel H1N1 influenza A pandemic. Clin. Microbiol. Rev. 25(2), 344-361 (2012).
8. Fedson DS. Pandemic influenza: A potential role for statins in treatment and prophylaxis. Clin. Infect. Dis. 43(2), 199-205 (2006).
9. Thomas JK, Noppenberger J. Avian influenza: A review. Am. J. Health Syst. Pharm. 64(2), 149-165 (2007). (Pubitemid 46395689)
10. Trampuz A, Prabhu RM, Smith TF, Baddour LM. Avian influenza: A new pandemic threat? Mayo Clin. Proc. 79(4), 523-530 (2004). (Pubitemid 38401772)
11. Leneva IA, Goloubeva O, Fenton RJ, Tisdale M, Webster RG. Efficacy of zanamivir against avian influenza A viruses that possess genes encoding H5N1 internal proteins and are pathogenic in mammals. Antimicrob. Agents Chemother. 45(4), 1216-1224 (2001). (Pubitemid 32231003)
12. Yen HL, Monto AS, Webster RG, Govorkova EA. Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/ Vietnam/1203/04 influenza virus in mice. J. Infect. Dis. 192(4), 665-672 (2005). (Pubitemid 41099316)
13. Govorkova EA, Webster RG. Combination chemotherapy for influenza. Viruses 2(8), 1510-1529 (2010).
14. Bearman GM, Shankaran S, Elam K. Treatment of severe cases of pandemic (H1N1) 2009 influenza: Review of antivirals and adjuvant therapy. Recent Pat. Antiinfect. Drug Discov. 5(2), 152-156 (2010).
15. Baranovich T, Webster RG, Govorkova EA. Fitness of neuraminidase inhibitor-resistant influenza A viruses. Curr. Opin. Virol. 1(6), 574-581 (2011).
16. Hurt AC, Chotpitayasunondh T, Cox NJ et al. Antiviral resistance during the 2009 influenza A H1N1 pandemic: Public health, laboratory, and clinical perspectives. Lancet Infect. Dis. 12(3), 240-248 (2012).
17. Singer AC, Nunn MA, Gould EA, Johnson AC. Potential risks associated with the proposed widespread use of Tamiflu. Environ. Health Perspect. 115(1), 102-106 (2007). (Pubitemid 46050289)
18. Tisoncik JR, Korth MJ, Simmons CP, Farrar J, Martin TR, Katze MG. Into the eye of the cytokine storm. Microbiol. Mol. Biol. Rev. 76(1), 16-32 (2012).
19. Clark NM, Lynch JP 3rd. Influenza: Epidemiology, clinical features, therapy, and prevention. Semin Respir. Crit. Care Med. 32(4), 373-392 (2011).
20. Vinogradova Y, Coupland C, Hippisley-Cox J. Risk of pneumonia in patients taking statins: Population-based nested case-control study. Br. J. Gen. Pract. 61(592), e742-e748 (2011).
21. Rothberg MB, Bigelow C, Pekow PS, Lindenauer PK. Association between statins given in hospital and mortality in pneumonia patients.J. Gen. Intern. Med. 27(3), 280-286 (2012).
22. An SC, Xu LL, Li FD, Bao LL, Qin C, Gao ZC. Triple combinations of neuraminidase inhibitors, statins and fibrates benefit the survival of patients with lethal avian influenza pandemic. Med. Hypotheses 77(6), 1054-1057 (2011).
23. Schlienger RG, Fedson DS, Jick SS, Jick H, Meier CR. Statins and the risk of pneumonia: A population-based, nested case-control study. Pharmacotherapy 27(3), 325-332 (2007). (Pubitemid 46327900)
24. Budd A, Alleva L, Alsharifi M et al. Increased survival after gemfibrozil treatment of severe mouse influenza. Antimicrob. Agents Chemother. 51(8), 2965-2968 (2007). (Pubitemid 47206237)
25. Zheng BJ, Chan KW, Lin YP et al. Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1 virus. Proc. Natl Acad. Sci. USA 105(23), 8091-8096 (2008).
26. Aldridge JR Jr, Moseley CE, Boltz DA et al. TNF/iNOS-producing dendritic cells are the necessary evil of lethal influenza virus infection. Proc. Natl Acad. Sci. USA 106(13), 5306-5311 (2009).
27. Moseley CE, Webster RG, Aldridge Jr. Peroxisome proliferator-activated receptor and AMP-activated protein kinase agonists protect against lethal influenza virus challenge in mice. Influenza Other Respi. Viruses 4(5), 307-311 (2010).
28. Woo PC, Tung ET, Chan KH, Lau CC, Lau SK, Yuen KY. Cytokine profiles induced by the novel swine-origin influenza A/H1N1 virus: Implications for treatment strategies. J. Infect. Dis. 201(3), 346-353 (2010).
29. Hui DS, Lee N, Chan PK. Clinical management of pandemic 2009 influenza A(H1N1) infection. Chest 137(4), 916-925 (2010).
30. Alleva LM, Cai C, Clark IA. Using complementary and alternative medicines to target the host response during severe influenza. Evid. Based Complement. Alternat. Med. 7(4), 501-510 (2010).
31. Butler D. Cheaper approaches to flu divide researchers. Nature 448(7157), 976-977 (2007). (Pubitemid 47345566)
32. Fedson DS. Confronting an influenza pandemic with inexpensive generic agents: Can it be done? Lancet Infect. Dis. 8(9), 571-576 (2008).
33. Bereswill S, Muñoz M, Fischer A et al. Anti-inflammatory effects of resveratrol, curcumin and simvastatin in acute small intestinal inflammation. Plos One 5(12), E15099 (2010).
34. Enserink M. Infectious disease: Old drugs losing effectiveness against flu; could statins fill gap? Science 309(5743), 1976-1977 (2005). (Pubitemid 41362292)
35. Fedson DS. Confronting the next influenza pandemic with anti-inflammatory and immunomodulatory agents: Why they are needed and how they might work. Influenza Other Respi. Viruses 3(4), 129-142 (2009).
36. Vandermeer ML, Thomas AR, Kamimoto L et al. Association between use of statins and mortality among patients hospitalized with laboratory-confirmed influenza virus infections: A multistate study. J. Infect. Dis. 205(1), 13-19 (2012).
37. Walsh EE. Statins and influenza: Can we move forward? J. Infect. Dis. 205(1), 1-3 (2012).
38. Jacobson JR, Dudek SM, Birukov KG et al. Cytoskeletal activation and altered gene expression in endothelial barrier regulation by simvastatin. Am. J. Respir. Cell Mol. Biol. 30(5), 662-670 (2004). (Pubitemid 38591217)
39. Jacobson JR, Barnard JW, Grigoryev DN, Ma SF, Tuder RM, Garcia JG. Simvastatin attenuates vascular leak and inflammation in murine inflammatory lung injury. Am. J. Physiol. 288(6), L1026-L1032 (2005). (Pubitemid 40695427)
40. Terblanche M, Smith TS, Adhikari NK. Statins, bugs and prophylaxis: Intriguing possibilities. Crit. Care 10(5), 168 (2006).
41. Haidari M, Ali M, Casscells SW, Madjid M. Statins block influenza infection by down-regulating rho/rho kinase pathway. Circulation 116, Abstract 147 (2007).
42. Furuta Y, Takahashi K, Fukuda Y et al. In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob. Agents Chemother. 46(4), 977-981 (2002). (Pubitemid 34260339)
43. Takahashi K, Furuta Y, Fukuda Y et al. In vitro and in vivo activities of T-705 and oseltamivir against influenza virus. Antivir. Chem. Chemother. 14(5), 235-241 (2003). (Pubitemid 37509379)
44. Sidwell RW, Barnard DL, Day CW et al. Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice. Antimicrob. Agents Chemother. 51(3), 845-851 (2007). (Pubitemid 46355265)
45. Smee DF, Hurst BL, Wong MH et al. Effects of the combination of favipiravir (T-705) and oseltamivir on influenza A virus infections in mice. Antimicrob. Agents Chemother. 54(1), 126-133 (2010).
46. Sidwell RW, Bailey KW, Wong MH, Huffman JH. In vitro and in vivo sensitivity of a non-mouse-adapted influenza A (Beijing) virus infection to amantadine and ribavirin. Chemotherapy 41(6), 455-461 (1995).
47. Sidwell RW, Smee DF, Huffman JH et al. In vivo influenza virus-inhibitory effects of the cyclopentane neuraminidase inhibitor RJW-270201. Antimicrob. Agents Chemother. 45(3), 749-757 (2001). (Pubitemid 32182020)
48. Reed LJ, Muench N. A simple method of estimating fifty per cent endpoints. Am. J. Hyg. 27, 493-497 (1938).
49. Sidwell RW, Huffman JH, Gilbert J et al. Utilization of pulse oximetry for the study of the inhibitory effects of antiviral agents on influenza virus in mice. Antimicrob. Agents Chemother. 36(2), 473-476 (1992).
50. Enserink M. Infectious disease. Old drugs losing effectiveness against flu; could statins fill gap? Science 309(5743), 1976-1977 (2005). (Pubitemid 41362292)
51. Rainsford KD. Influenza ("Bird Flu"), inflammation and anti-inflammatory/analgesic drugs. Inflammopharmacology 14(1-2), 2-9 (2006).
52. Frost FJ, Petersen H, Tollestrup K, Skipper B. Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. Chest 131(4), 1006-1012 (2007). (Pubitemid 46608700)
53. Hak E, Hoes AW. Statins and outcomes in patients with pneumonia: Appreciating bias and precision in study. BMJ 333(7578), 1124 (2006). (Pubitemid 44863666)
54. Forrester JS, Libby P. The inflammation hypothesis and its potential relevance to statin therapy. Am. J. Cardiol. 99(5), 732-738 (2007).
55. Amet T, Nonaka M, Dewan MZ et al. Statin-induced inhibition of HIV-1 release from latently infected U1 cells reveals a critical role for protein prenylation in HIV-1 replication. Microbes Infect. 10(5), 471-480 (2008).
56. Liu S, Rodriguez AV, Tosteson MT. Role of simvastatin and methyl-beta-cyclodextrin [corrected] on inhibition of poliovirus infection. Biochem. Biophys. Res. Comm. 347(1), 51-59 (2006). (Pubitemid 44015649)
57. Gower TL, Graham BS. Antiviral activity of lovastatin against respiratory syncytial virus in vivo and in vitro. Antimicrob. Agents Chemother. 45(4), 1231-1237 (2001). (Pubitemid 32231005)
58. Katano H, Pesnicak L, Cohen JI. Simvastatin induces apoptosis of Epstein-Barr virus (EBV)-transformed lymphoblastoid cell lines and delays development of EBV lymphomas. Proc. Natl Acad. Sci. USA 101(14), 4960-4965 (2004). (Pubitemid 38469185)
59. Bader T, Korba B. Simvastatin potentiates the anti-hepatitis B virus activity of FDA-approved nucleoside analogue inhibitors in vitro. Antiviral Res. 86(3), 241-245 (2010).
60. Mihaila RG, Nedelcu L, Fratila O et al. Effects of simvastatin in patients with viral chronic hepatitis C. Hepatogastroenterology 58(109), 1296-1300 (2011).
61. Liu Z, Guo Z, Wang G et al. Evaluation of the efficacy and safety of a statin/caffeine combination against H5N1, H3N2 and H1N1 virus infection in BALB/c mice. Eur. J. Pharm. Sci. 38(3), 215-223 (2009).
62. Radigan KA, Urich D, Misharin AV et al. The effect of rosuvastatin in a murine model of influenza A infection. Plos One 7(4), E35788 (2012).
63. Heinzel FP, Sadick MD, Holaday BJ, Coffman RL, Locksley RM. Reciprocal expression of interferon gamma or interleukin 4 during the resolution or progression of murine leishmaniasis. Evidence for expansion of distinct helper T cell subsets. J. Exp. Med. 169(1), 59-72 (1989). (Pubitemid 19035542)
64. Srivastava B, Blazejewska P, Hessmann M et al. Host genetic background strongly influences the response to influenza a virus infections. Plos One 4(3), E4857 (2009).
65. Taubenberger JK, Morens DM. The pathology of influenza virus infections. Ann. Rev. Pathol. 3, 499-522 (2008). (Pubitemid 351488291)
66. Zarogiannis SG, Noah JW, Jurkuvenaite A, Steele C, Matalon S, Noah DL. Comparison of ribavirin and oseltamivir in reducing mortality and lung injury in mice infected with mouse adapted A/California/04/2009 (H1N1). Life Sciences 90(11-12), 440-445 (2012).
67. Itoh Y, Shinya K, Kiso M et al. In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature 460(7258), 1021-1025 (2009).
68. Walsh KB, Teijaro JR, Wilker PR et al. Suppression of cytokine storm with a sphingosine analog provides protection against pathogenic influenza virus. Proc. Natl Acad. Sci. USA 108(29), 12018-12023 (2011).
69. Marsolais D, Hahm B, Walsh KB et al. A critical role for the sphingosine analog AAL-R in dampening the cytokine response during influenza virus infection. Proc. Natl Acad. Sci. USA 106(5), 1560-1565 (2009).
70. Marsolais D, Hahm B, Edelmann KH et al. Local not systemic modulation of dendritic cell S1P receptors in lung blunts virus-specific immune responses to influenza. Mol. Pharmacol. 74(3), 896-903 (2008).
71. Lau YF, Tang LH, Ooi EE. A TLR3 ligand that exhibits potent inhibition of influenza virus replication and has strong adjuvant activity has the potential for dual applications in an influenza pandemic. Vaccine 27(9), 1354-1364 (2009).
72. Lau YF, Tang LH, Ooi EE, Subbarao K. Activation of the innate immune system provides broad-spectrum protection against influenza A viruses with pandemic potential in mice. Virology 406(1), 80-87 (2010).
73. Evseenko VA, Bukin EK, Zaykovskaya AV et al. Experimental infection of H5N1 HPAI in BALB/c mice. Virol. J. 4, 77 (2007).
74. Cheng X, Xu Q, Song E, Yang CF, Kemble G, Jin H. The hemagglutinin protein of influenza A/Vietnam/1203/2004 (H5N1) contributes to hyperinduction of proinflammatory cytokines in human epithelial cells. Virology 406(1), 28-36 (2010).